Scientific Symposium
Optimizing Safety and Efficacy: Exploring the Extended Interval Dosing of Natalizumab for JCV Positive Patients
27 Apr 2024
13:00 - 15:00
Cordis Hotel, Mongkok
Speaker(s)
Mrs. Derry Thomas
Medical Consultant
Eisai Hong Kong
Dr. Richard Li
Council Member
HKMSS
On 27 April 2024, the HKMSS organized a scientific symposium titled ‘Optimizing Safety and Efficacy: Exploring the Extended Interval Dosing of Natalizumab for JCV Positive Patients’.
In the first talk, Mrs Derry Thomas, a medical consultant of Eisai Hong Kong, shared with us the latest data on extended interval dosing of Natalizumab, focusing on how a 6-weekly interval use of the drug reduces the risk of PML while retaining its efficacy.
In the second talk, Dr. Richard Li from our council shared three local cases who have been treated with Natalizumab. The cases highlighted several challenges faced by physicians while treating patients with active RRMS. The session was followed by Q&A from the floor.
We would like to thank all our participants for making this event a success!